Here, we provide evidence that oral administration of a small molecule inhibitor of the amino acid transporter SLC6A19 can block renal neutral amino acid reabsorption and may provide a compelling therapeutic approach for PKU and related disorders of amino acid metabolism. This evidence concerns the gene SLC6A19 and phenylketonuria.